Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
188Re-MN-16ET
- Development stage
- Preclinical
- Lead developer
- National Atomic Research Institute
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intra-arterial
01
Overview
188Re-MN-16ET is a therapeutic radiopharmaceutical developed for the treatment of liver malignancies, specifically hepatocellular carcinoma (HCC). It consists of the beta-emitting radioisotope rhenium-188 (188Re) complexed with a lipophilic N2S2 tetradentate ligand, N-[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3-[2-(triphenylmethyl)thioethyl]octadecanoate (H3MN-16ET). The complex is typically formulated in Lipiodol (ethiodized oil), which acts as a carrier for selective delivery to hypervascular liver tumors via transcatheter arterial embolization (TAE). Once administered intra-arterially, the radiopharmaceutical is selectively retained within the tumor vasculature, delivering localized ionizing radiation to induce tumor cell death while minimizing exposure to healthy liver tissue. Preclinical studies in rat models have demonstrated significant tumor retention and improved survival rates compared to controls.
- Other names
- 188Re-MN-16ET/LipiodolRe-188 MN-16ET lipiodolRe188 MN-16ET lipiodolRe 188 MN-16ET lipiodolrhenium-188 MN-16ETrhenium188 MN-16ETrhenium 188 MN-16ET
02
Targets
DNA
Beyond the preview
Go deeper on 188Re-MN-16ET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 188Re-MN-16ET.